Tone mix
Week by week 52 weeks
Share of Sanofi American Depositary Shares (Each representing one-half of one ordinary share)'s 702 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Aug 24, 2026 · tone -68Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?-72
- Week of Sep 14, 2026 · tone +74Cheplapharm to take over 20 medicines and three sites from Sanofi+70
- Week of Jul 20, 2026 · tone -30Sanofi Ends Clinical Development Of Amlitelimab For Atopic Dermatitis-65
- Week of Sep 21, 2026 · tone +73Sanofi and Cheplapharm forge new medicines partnership+56
- Week of Dec 15, 2025 · tone -27Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades-53
- Week of Jul 27, 2026 · tone -20Sanofi's New Leadership Faces Looming Patent Cliff-48
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Sanofi American Depositary Shares (Each representing one-half of one ordinary share) in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 24 | +40 |
| Last 30 sessions | 64 | +47 |
| Last 90 sessions | 154 | +26 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Thursday, November 5, 2026
5 headlines, average tone -22: 2 positive, 0 neutral and 3 negative. Showing all 5.
- www.prnewswire.com · 1 outletCNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation IndexPositive
- econotimes.com · 1 outletSanofi Ends Phase 1 Trial, Terminates SAR448272 Program, Nurix SaysNegative
- www.rttnews.com · 1 outletNurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader ProgramNegative
- www.biopharmadive.com · 1 outletSanofi stops development of Nurix-partnered immune drugNegative
- www.middleeaststar.com · 1 outletKhalifa University, Sanofi partner to advance genomic research into Asthma, COPD in UAEPositive
Show the table · 5 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index | www.prnewswire.com | 1 | Positive |
| Sanofi Ends Phase 1 Trial, Terminates SAR448272 Program, Nurix Says | econotimes.com | 1 | Negative |
| Nurix Shares Fall 40% After Sanofi Discontinues STAT6 Degrader Program | www.rttnews.com | 1 | Negative |
| Sanofi stops development of Nurix-partnered immune drug | www.biopharmadive.com | 1 | Negative |
| Khalifa University, Sanofi partner to advance genomic research into Asthma, COPD in UAE | www.middleeaststar.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, November 3, 2026
5 headlines, average tone +34: 2 positive, 3 neutral and 0 negative. Showing all 5.
- www.fool.com · 2 outletsSanofi (SNY) Q3 2026 Earnings Call TranscriptNeutral
- www.themarketsdaily.com · 1 outletSanofi (NASDAQ: SNY) raises full-year outlook and Dupixent sales jump 34.8%Positive
- www.ibtimes.com.au · 1 outletRegeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third QuarterPositive
- www.selectscience.net · 1 outletScionxBio and Sanofi partner on xRNA - SelectScience newsNeutral
- healthcare-digital.com · 1 outletRegeneron Builds on Sanofi Partnership in Strong Q3 EarningsNeutral
Show the table · 5 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sanofi (SNY) Q3 2026 Earnings Call Transcript | www.fool.com | 2 | Neutral |
| Sanofi (NASDAQ: SNY) raises full-year outlook and Dupixent sales jump 34.8% | www.themarketsdaily.com | 1 | Positive |
| Regeneron Stock Jumps 13% to 52-Week High as Sanofi Dupixent Windfall Powers a Blockbuster Third Quarter | www.ibtimes.com.au | 1 | Positive |
| ScionxBio and Sanofi partner on xRNA - SelectScience news | www.selectscience.net | 1 | Neutral |
| Regeneron Builds on Sanofi Partnership in Strong Q3 Earnings | healthcare-digital.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, November 2, 2026
6 headlines, average tone +46: 4 positive, 1 neutral and 1 negative. Showing all 6.
- 247wallst.com · 1 outletSanofi Tops Q3 2026 Expectations as Dupixent Sales Reach $6.36 BillionPositive
- www.investors.com · 1 outletRegeneron, Sanofi Surge As Dupixent Wallops Sales ForecastsPositive
- seekingalpha.com · 1 outletRegeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4 (NASDAQ:REGN)Positive
- www.iraq-businessnews.com · 1 outletIraq in Talks with Sanofi on Vaccine Sourcing | Iraq Business NewsPositive
- 247wallst.com · 1 outletRegeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks UpNegative
- www.livemint.com · 1 outletDividend, stock split, bonus record date alert 2-8 Nov week: Infosys, Mazagon Dock, Coal India, Sanofi and other sharesNeutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sanofi Tops Q3 2026 Expectations as Dupixent Sales Reach $6.36 Billion | 247wallst.com | 1 | Positive |
| Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts | www.investors.com | 1 | Positive |
| Regeneron expects 2027 R&D expense to rise by a mid-teens percentage while recording a $1B Sanofi upfront payment in Q4 (NASDAQ:REGN) | seekingalpha.com | 1 | Positive |
| Iraq in Talks with Sanofi on Vaccine Sourcing | Iraq Business News | www.iraq-businessnews.com | 1 | Positive |
| Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up | 247wallst.com | 1 | Negative |
| Dividend, stock split, bonus record date alert 2-8 Nov week: Infosys, Mazagon Dock, Coal India, Sanofi and other shares | www.livemint.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Friday, October 30, 2026
6 headlines, average tone +72: 5 positive, 1 neutral and 0 negative. Showing all 6.
- www.equitybulls.com · 1 outletSanofi India delivers strong Q3 2026 performancePositive
- www.rttnews.com · 1 outletSanofi Q3 Net Profit, Business Profit Climb; Lifts FY26 OutlookPositive
- www.rttnews.com · 1 outletSanofi Q3 Profit Climbs On Dupixent Growth; Raises FY26 Guidance; Stock UpPositive
- www.prnewswire.com · 1 outletNovavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropePositive
- www.rttnews.com · 1 outletNovavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock UpPositive
- econotimes.com · 1 outletNovavax Reports $125 Million Milestone After Sanofi Trial DosingNeutral
Show the table · 6 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sanofi India delivers strong Q3 2026 performance | www.equitybulls.com | 1 | Positive |
| Sanofi Q3 Net Profit, Business Profit Climb; Lifts FY26 Outlook | www.rttnews.com | 1 | Positive |
| Sanofi Q3 Profit Climbs On Dupixent Growth; Raises FY26 Guidance; Stock Up | www.rttnews.com | 1 | Positive |
| Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe | www.prnewswire.com | 1 | Positive |
| Novavax Gains $125 Mln Payment As Sanofi Begins Phase 3 Combination Vaccine Trial; Stock Up | www.rttnews.com | 1 | Positive |
| Novavax Reports $125 Million Milestone After Sanofi Trial Dosing | econotimes.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 29, 2026
2 headlines, average tone +100: 2 positive, 0 neutral and 0 negative. Showing all 2.
- econotimes.com · 1 outletSanofi Consumer Healthcare India Profit Rises 22%; Shares Reach Reported HighPositive
- www.livemint.com · 1 outletSanofi Consumer share price jumps 11% after strong Q3 results | Is it time to book profits? Check target, rationalePositive
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Sanofi Consumer Healthcare India Profit Rises 22%; Shares Reach Reported High | econotimes.com | 1 | Positive |
| Sanofi Consumer share price jumps 11% after strong Q3 results | Is it time to book profits? Check target, rationale | www.livemint.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Sanofi American Depositary Shares (Each representing one-half of one ordinary share), not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.